Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 18, 2003

View Archived Issues

Company Profile: Sirus Pharmaceuticals

Local analgesic effects described for tricyclic antidepressants in rats

Aripiprazole is safe and effective in the treatment of schizophrenia and schizoaffective disorders

Hemispherx enters research agreement with Johann Wolfgang Goethe U. Hospital

Alzheimer's vaccine goal of new collaboration

AIDS Healthcare Foundation to urge FDA to withdraw Trizivir approval

OvuLook saliva-based ovulation system launched

Generex completes Antigen Express acquisition

Transkaryotic Therapies retakes Factor VIII gene therapy rights from Wyeth

Santen seeks Japanese manufacturing approval for vernal keratoconjunctivitis treatment

Elite authorizes merger negotiations with Nostrum

Titan updates key program status

New, potent inhibitors of rat 17alpha-hydroxylase/C17,20-lyase

Potent and selective non-imidazole human histamine H4 receptor antagonists

Affimed and Dyax enter crosslicensing agreement for phage display technologies

Merck KGaA acquires ProteoPlex

Novel nAchR ligands under study at Sanofi-Synthelabo

Acadia patent covers new muscarinic agonists with utility in cognition disorders

Novel 5-HT2A receptor inverse agonists evaluated by Acadia scientists

New beta-secretase inhibitors identified by Elan and Pharmacia team

Novel 5-HT2C receptor ligands and their use in depression and anxiety

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan. 13, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for January 13, 2025
Caplyta star shines as J&J takes Intra-Cellular in $14.6B deal
BioWorld
The J.P. Morgan (JPM) Healthcare Conference in San Francisco kicked off with a resounding bang as Johnson & Johnson (J&J) disclosed plans to acquire...
Proteomics study explores how protein changes influence disease
BioWorld Science
Fourteen global pharma companies are getting together to conduct the largest proteomics study to date, analyzing 600,000 blood samples held in the UK Biobank to...
Type 1 diabetes breakthrough? Sana threads key ‘islet,’ SC-451 to advance
BioWorld
Sana Biotechnology Inc. CEO Steve Harr said “cool and transformative science” led to his firm’s latest strides in type 1 diabetes, and the “very generalizable...

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.